We are live on ! Find out more
FLNA

Filana Therapeutics

97 hedge funds and large institutions have $22.1M invested in Filana Therapeutics in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 33 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more call options, than puts

Call options by funds: $2.27M | Put options by funds: $1.29M

7.41% less ownership

Funds ownership: 32.73%25.33% (-7.4%)

13% less capital invested

Capital invested by funds: $25.6M → $22.1M (-$3.42M)

17% less funds holding

Funds holding: 11797 (-20)

30% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 33

53% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 38

Holders
97
Holders Change
-20
Holders Change %
-17.09%
% of All Funds
1.28%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
23
Reduced
33
Closed
38
Calls
$2.27M
Puts
$1.29M
Net Calls
+$986K
Net Calls Change
-$372K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.93M -$484K -272,235 -11%
BlackRock
2
BlackRock
New York
$2.8M -$3.43M -1,929,073 -56%
Two Sigma Advisers
3
Two Sigma Advisers
New York
$1.78M +$133K +75,000 +8%
JP Morgan Chase
4
JP Morgan Chase
New York
$1.37M -$58.6K -32,955 -4%
Goldman Sachs
5
Goldman Sachs
New York
$1.11M +$208K +116,830 +24%
Two Sigma Investments
6
Two Sigma Investments
New York
$953K +$167K +93,934 +22%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$947K -$896K -503,720 -49%
Millennium Management
8
Millennium Management
New York
$856K +$841K +472,782 New
Morgan Stanley
9
Morgan Stanley
New York
$815K +$132K +74,197 +20%
GC
10
GMT Capital
Georgia
$815K
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$808K -$188K -105,591 -19%
Jane Street
12
Jane Street
New York
$613K +$110K +61,765 +22%
CSS
13
Cubist Systematic Strategies
Connecticut
$561K +$551K +309,701 New
Charles Schwab
14
Charles Schwab
California
$480K -$171K -95,963 -27%
TCM
15
Tang Capital Management
California
$434K +$70.9K +39,820 +20%
State Street
16
State Street
Massachusetts
$393K -$1.17M -656,619 -75%
Group One Trading
17
Group One Trading
Illinois
$392K +$216K +121,429 +128%
UBS Group
18
UBS Group
Switzerland
$344K -$633K -355,730 -65%
SPS
19
Susquehanna Portfolio Strategies
Pennsylvania
$242K +$237K +133,443 New
Squarepoint
20
Squarepoint
New York
$193K +$73.6K +41,345 +63%
Northern Trust
21
Northern Trust
Illinois
$184K -$476K -267,415 -72%
HF
22
HRT Financial
New York
$171K +$169K +94,855 New
BNP Paribas Financial Markets
23
BNP Paribas Financial Markets
France
$165K +$1.17K +660 +0.7%
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$153K +$149K +83,754 +7,777%
Marshall Wace
25
Marshall Wace
United Kingdom
$130K +$128K +71,714 New

FLNA Hedge Fund Activity: Q2 2025 in Review

97 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q2 2025, worth a combined $22.1M — down 13% from $25.6M a quarter earlier.

Sellers outnumbered buyers: 38 funds closed out of FLNA and 18 opened new positions — a net loss of 20 holders — while 33 trimmed existing stakes and 23 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $841K. The largest seller was BlackRock, cutting an estimated $3.43M.

  • 97 institutional investors held Filana Therapeutics (FLNA) as of Q2 2025, down from 117 in Q1 2025.
  • Funds reported $22.1M of Filana Therapeutics stock for Q2 2025, down 13% quarter-over-quarter.
  • 18 funds opened new Filana Therapeutics positions in Q2 2025 and 38 closed out, a net change of -20 holders.
  • The largest Filana Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $841K added.
  • The largest Filana Therapeutics seller in Q2 2025 was BlackRock, an estimated $3.43M sold.

Based on aggregated 13F filings for Q2 2025.